A Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis
Sponsor: US National Institute of Allergy and Infectious Diseases (NIAID)
Protocol Summary: A5225 was a phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an induction-consolidation strategy of high-dose fluconazole alone for the treatment of cryptococcal meningitis (CM) in HIV-infected participants.
Years: 2010 – present
Investigator: James Hakim, MBChB, FRCP
Location: Parirenyatwa CRS
Comments are closed.